Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients.
Pediatric blood & cancer
Twenty-eight patients were maintained on subcutaneous immunoglobulin replacement for persistent B-cell aplasia and agammaglobulinemia following CD19-targeted chimeric antigen receptor T-cell therapy for B-cell lymphoblastic leukemia. Patients were transitioned from intravenous to subcutaneous immunoglobulin replacement at a median of 11.5 months (range, 4-20). Increasing serum IgG level was significantly associated with a lower rate of sinopulmonary infection (P = 0.0072). The median serum IgG level during infection-free periods was 1000 mg/dL (range, 720-1430), which was significantly higher than IgG levels in patients with sinopulmonary infections. As such, we recommend maintaining a goal IgG level > 1000 mg/dL to provide optimal protection.
Adolescent, Adult, Cell- and Tissue-Based Therapy, Child, Preschool, Female, Follow-Up Studies, Humans, Immunoglobulins, Injections, Subcutaneous, Male, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Receptors, Antigen, T-Cell, Retrospective Studies, T-Lymphocytes, Young Adult
Arnold, D., Maude, S., Callahan, C., DiNofia, A., Grupp, S., & Heimall, J. (2020). Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients.. Pediatric blood & cancer, 67 (3), 28092-28092. https://doi.org/31793170